Protease Activated Receptor-2 as an Imperative Target in Nociceptive Responses: A Minireview

Authors

  • Nilesh Mahajan Padmavathi College of Pharmacy, Periyanahalli, Dharmapuri, Tamil Nadu, India
  • Vaidhyalingam V Department of Pharmacology, Padmavathi College of Pharmacy, Periyanahalli, Tamilnadu, India

Abstract

 

PARs (protease-activated receptors) are a family of seven-transmembrane G-protein coupled receptor for proteases from circulation, inflammatory cells and endothelial tissues. To date, four members of PAR family have been cloned, namely PAR1 to PAR4. This minireview focuses on role of PAR2 receptor in inflammatory and nociceptive processes. Numerous studies documented for activation of PAR2 receptors through several proteases suggests its role in pain and inflammation. However, mechanism of PAR2 underlying its downregulation is poorly understood. Several screening tools for study of receptor mechanism with agonist and antagonist have been developed. Moreover, study with knockout and transgenic mice so far contributed in this regard suggests possibility of PAR2 selective antagonist as a useful drug for the treatment of pain and inflammatory disorders.

Keywords: antagonist, hyperalgesia, inflammation, nociceptive, receptors, targets

Downloads

Published

2021-01-11

Issue

Vol. 1 No. 1 (2011)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.